Physician profile
Christopher Morris
NPI 1417446618
$2,409.52
in general payments reported to CMS, 2019-2025
37 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $639 · 2022: $512 · 2024: $654 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $498.31 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.08 | 2021-2024 | Jardiance, Tradjenta |
| Abbvie INC. | $183.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $147.37 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $133.88 | 2021-2025 | |
| Amgen INC. | $124.37 | 2021-2025 | Repatha, Evenity, Krystexxa |
| Eisai INC. | $93.59 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $80.81 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $79.50 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $74.67 | 2021-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $69.70 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Philips North America LLC | $61.29 | 2025 | Mcot, Ambulatory Monitoring & Diagnostics Undivided |
| Exact Sciences Corporation | $50.07 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $38.11 | 2022 | |
| Pfizer INC. | $36.46 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $34.10 | 2025 | Inspire |
| Antares Pharma, INC. | $31.18 | 2022 | |
| Bard Peripheral Vascular, INC. | $27.67 | 2024 | Rotarexs 6 F X 135 Cm |
| Corcept Therapeutics | $26.45 | 2025 | Korlym |
| Abbott Laboratories | $24.44 | 2025 | Freestyle Libre 3 |
| Axonics, INC. | $22.00 | 2024 | Axonics |
| Kyowa Kirin, INC. | $21.85 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $21.70 | 2022 | |
| Medtronic, INC. | $19.72 | 2024 | Minimed 780g |
| Teleflex LLC | $19.27 | 2025 | Barrigel |
| Ardelyx, INC. | $18.84 | 2024 | Ibsrela |
| Verity Pharmaceuticals INC. | $18.24 | 2025 | Tlando |
| Abiomed | $18.10 | 2024 | Impella |
| Gilead Sciences, INC. | $17.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $14.14 | 2022 | |
| Daiichi Sankyo INC. | $13.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.73 | 2021 | |
| Amarin Pharma, INC. | $13.61 | 2022 | |
| 180 Medical, INC. | $13.43 | 2021 | |
| Seqirus USA INC | $13.09 | 2024 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.